Tobira Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 11, 2015 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and immuno-inflammatory diseases, announced that the company will present a business overview and update at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015 at 8:40 a.m. Pacific Time in Las Vegas.

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.tobiratherapeutics.com. Replays of the presentation will be available at the same location for 90 days following the conference.

About Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and HIV.  Tobira is actively enrolling patients in a Phase 2b clinical trial called CENTAUR to evaluate CVC in patients with NASH and liver fibrosis.  For additional information on the CENTAUR study, please visit clinicaltrials.gov using the identifier NCT02217475 or www.centaurstudy.com.  Learn more about Tobira at www.tobiratherapeutics.com.

Tobira Contacts:
Chris Peetz
Chief Financial Officer
Tobira Therapeutics
(650) 351-5018
[email protected]

Mark Corbae
Canale Communications
(619) 849-5375
[email protected] 

SOURCE Tobira Therapeutics, Inc.

Related Links

http://www.tobiratherapeutics.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED